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Abstract 
Background: Prostate cancer is the most frequently diagnosed cancer in men and the third leading cause of cancer 
related deaths among men living in developed countries. Biomarkers that predict disease outcome at the time of 
initial diagnosis would substantially aid disease management.
Results: Proteins extracted from formalin-fixed paraffin-embedded tissue were identified using nanoflow liquid chro-
matography-MALDI MS/MS or after separation by one- or two-dimensional electrophoresis. The proteomics data have 
been deposited to the ProteomeXchange with identifier PXD000963. A list of potential biomarker candidates, based 
on proposed associations with prostate cancer, was derived from the 320 identified proteins. Candidate biomarkers 
were then examined by multiplexed Western blotting of archival specimens from men with premetastatic disease and 
subsequent disease outcome data. Annexin A2 provided the best prediction of risk of metastatic disease (log-rank Chi 
squared p = 0. 025). A tumor/control tissue >2-fold relative abundance increase predicted early biochemical failure, 
while <2-fold change predicted late or no biochemical failure.
Conclusions: This study confirms the potential for use of archival FFPE specimens in the search for prognostic bio-
markers for prostate cancer and suggests that annexin A2 abundance in diagnostic biopsies is predictive for meta-
static potential. Protein profiling each cancer may lead to an overall reduction in mortality from metastatic prostate 
cancer as well as reduced treatment associated morbidity.
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Background
Prostate cancer (PCa) is the most frequently diagnosed 
cancer in men and the third leading cause of cancer 
related deaths among men living in developed countries 
[1]. Serum prostate-specific antigen (PSA) testing used 
to assist in making the diagnosis of PCa is a useful tool, 
but it has some limitations. It suffers from poor specific-
ity, and elevation of the serum PSA is often due to non-
malignant causes. The biopsies performed as a result of 
an elevated serum PSA result in the detection of some 
clinically irrelevant tumors (over-diagnosis) which will 
not trouble affected men during their lifetimes. Finally, 
the degree of elevation of the serum PSA level at the time 
of diagnosis does not assist in predicting how aggres-
sively the cancer will behave.
Trial 96.01 was the first of two large randomized tri-
als run by the Trans-Tasman Radiation Oncology Group 
(TROG) investigating new treatment strategies for locally 
advanced PCa. The trial end points at 10  years were 
reported in 2011 [2]. In trial patients, there appeared to 
be three distinct patterns of behaviour when the can-
cer relapsed: one with a short PSA doubling time of less 
than 4  months, one with an intermediate duration PSA 
doubling time of 4–9 months, and the other with a PSA 
doubling time greater than 9  months [3]. The polariza-
tion of biological behaviour on relapse suggests there are 
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inherent differences between cancers responsible for the 
speed at which they grow and their biological behaviour. 
If this hypothesis is correct, then PCa could have a num-
ber of characteristic patterns of protein expression capa-
ble of informing the patient and clinician how the cancer 
is likely to behave. Identification of men at the time of 
diagnosis that are at high risk of developing biochemi-
cal relapse (PSA failure) is fundamental to improving the 
treatment of locally advanced PCa, and to reducing the 
over-treatment of men that currently occurs. Trial 96.01 
showed that PSA failure was predominantly due to the 
development of metastatic disease [2], and risk of PSA 
failure can therefore be used as a surrogate for risk of 
metastatic disease.
We therefore investigated protein variation associated 
with risk of PSA failure using archival formalin-fixed 
paraffin-embedded (FFPE) tissue from men for whom 
disease outcome details was already known. A dataset of 
proteins was constructed using three proteomic strate-
gies: (1) two-dimensional electrophoresis (2DE) followed 
by MALDI MS/MS of tryptic digests of protein spots; (2) 
Gel-MS/MS based on protein separation by one-dimen-
sional SDS-polyacrylamide gel electrophoresis followed 
by protein identification by MALDI MS/MS of tryptic 
digests of multiple bands cut from the gels; (3) LC MS/
MS carried out by reversed phase HPLC of tryptic digests 
followed by off-line MALDI MS/MS of the chromatog-
raphy fractions. Potential prognostic proteins selected 
from the dataset were examined using Western blotting, 
and four putative prognostic markers were tested against 
proteins extracted from an independent set of archi-
val sections from patients with known disease outcome. 
Currently we report a study of protein variation associ-
ated with disease outcome that has been carried out to 
identify candidates for analysis in a larger, independent, 
sample set. We anticipate that detection of prognostic 
proteins would be used principally to determine which 
cancers in older patients require treatment. A secondary 
objective is to determine which younger patients might 
benefit from intensification of their treatment at time of 
diagnosis. We expect that protein profiling of PCa biopsy 
specimens would be performed at the time of initial diag-
nosis of disease for prediction of the likely behavior of the 
cancer.
Results and discussion
Initially, a protein database was established using 2DE, 
Gel-MS/MS, and LC–MS/MS of proteins extracted from 
tumor regions of archival FFPE prostate tissue. Although 
2DE separations gave relatively few discrete protein spots 
(Additional file 1) MALDI MS of tryptic digests of pro-
tein spots from these gels resulted in identification of 28 
unique proteins including PSA (kallikrein-3). Western 
blotting with anti-PSA suggested multiple forms of this 
protein (Additional file  2), or of related kallikreins, but 
only the most abundant form was identified by MS. Gel-
MS/MS identified 47 non-redundant proteins with at 
least one matched peptide, and using LC–MS/MS 242 
non-redundant proteins were identified. Of the 242 pro-
teins identified by LC–MS/MS, 190 were not detected by 
either of the other methods. Identity scores and %  cov-
erage for protein identification were often low, prob-
ably due to covalent modification of proteins during 
tissue processing [4]. In total, 320 non-redundant pro-
teins were identified (Fig. 1, Additional files 3, 4, 5). The 
greatest numbers of identifications were of high abun-
dance cytoplasmic, cytoskeletal and organelle matrix 
proteins including nuclear histones, ribosomal proteins 
and organelle Rabs that are detected during proteomic 
analysis of many mammalian tissues including pros-
tate. Given the greater number of proteins identified by 
LC–MS/MS, strategies including LC–MS/MS of bands 
excised from SDS PAGE gels that enhance detection of 
proteins including integral membrane proteins should 
be investigated in future studies. For comparison, there 
are relatively few published analyses of FFPE prostate tis-
sue since the initial publication of Hood et al. who used 
Fig. 1 Summary of proteins identified by 2DE, Gel-MS/MS, and 
LC–MS/MS of radical prostatectomy sections. For Gel-MS/MS, total 
protein samples extracted from FFPE tissue were separated by 1DE 
and each lane was sliced horizontally into 30–35 slices. Proteins in 
each slice were trypsin digested and the resulting peptide mixtures 
analysed by MALDI TOF/TOF. For LC–MS/MS, total protein extracted 
from FFPE tissue was reduced, alkylated, and trypsin digested. Digests 
were then separated in triplicate by HPLC using a TEMPO LC-MALDI 
spotter system. Eluted peptides (16 s intervals) were mixed on-line 
with CHCA matrix and spotted for TOF/TOF analysis
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LC–MS/MS to examine tryptic digests of extracts from 
benign prostate hyperplasia and cancer regions of a FFPE 
prostate block [5]. Subsequent reports using frozen tissue 
include 2D-DIGE analysis of prostatectomy specimens 
from patients with or without relapse [6], and an iTRAQ 
comparison of tissue from localized and advanced pros-
tate cancer patients [7].
Selection of a set of potential prognostic biomarkers 
was carried out by interfacing the database of identi-
fied proteins with a search of the Human Protein Atlas 
(http://www.proteinatlas.org/ version 12) for candidates 
with known immunological reactivity with PCa (Fig.  2). 
Human Protein Atlas proteins corresponding to keyword 
“Prostate”; protein class “Candidate cancer biomarkers”; 
HPA evidence “High”, and filtered for IHC staining in 
PCa, when interfaced with the MS datasets gave a set of 
12 proteins common to both lists (Additional file 6). Five 
of these candidates were selected on the basis of known 
associations with PCa (see below) for initial examination 
by Western blotting of FFPE extracts of radical prosta-
tectomy tissue but only four were detected at sufficient 
abundance for subsequent analysis. This included PSA 
and three other proteins that have been associated with 
PCa: annexin A2 (ANXA2) [8–11], zinc-alpha-2-glyco-
protein (AZGP1, ZAG) [12–14] and peroxiredoxin-1 
(PRDX1) [15, 16]. Positive reactions at the expected 
molecular masses were obtained for each of these pro-
teins, and after optimising primary and secondary anti-
body dilutions a multiplexing strategy was developed 
by blotting with a mixture of antibodies to all four pro-
teins plus actin as a loading control (Fig.  3). The multi-
plex strategy allowed detection of several proteins from a 
single blot and facilitated analysis of the small amount of 
tissue that was harvested from some FFPE blocks. Heat 
shock protein beta-1 was also detected by Western blot-
ting but often with low intensity signals near the thresh-
old for detection and was not included in the statistical 
analysis.
Tumor and control tissue regions excised from FFPE 
sections from 16 patients, independent of tissue used 
for the prior MS analyses, were examined using a mul-
tiplexing method. The samples for multiplexed West-
ern blotting were chosen to represent a range of disease 
outcomes (time to biochemical failure) with five cases 
>100 months, five cases ≤40 months, and six “intermedi-
ate” 50–87 months. Measured protein abundances were 
normalized to actin amounts and the tumor/control 
abundance ratio for each protein was used for analysis of 
association with time to biochemical failure. The ratios 
of tumor to control tissue values were used to correct 
for possible inter-individual differences in protein abun-
dance not related to PCa. In most cases the amount of 
tissue available from the 16 cases was only sufficient for 
a single extraction and Western blot. Following detec-
tion of the associations of ANXA2 and PSA with disease 
outcome (see below), analytical reproducibility for the 
two proteins was examined by replicate analyses of pro-
teins extracted from FFPE radical prostatectomy tissue. 
Four separate protein extractions were carried out from 
a radical prostatectomy block and the set of four extracts 
was each analyzed twice by Western blotting using 15 μg 
of protein on each gel. CVs for the normalized, relative 
abundance values (ANXA2 or PSA normalized against 
the actin loading control) of the four extracts ranged 
from 4.4 to 9.5 % for ANXA2 and 2.1–6.5 % for PSA, with 
less than 6.5  % variation for either protein between the 
duplicate Western blots.
For each protein of interest in the 16 cases the Kaplan–
Meier estimator curves of the “survival” (biochemical 
failure) function were stratified using cut points deter-
mined before the analysis and the failure curves com-
pared using the log-rank Chi squared test. For two of the 
proteins there was a significant difference in the failure 
curves between the strata predefined by differences in 
protein abundance measurements. The Kaplan–Meier 
curves for ANXA2 (Fig. 4) demonstrate that for men with 
greater than a two-fold increase in ANXA2 abundance 
in tumor relative to control tissue this appears to predict 
those men who will experience early biochemical failure 
during the trial period (log-rank Chi squared p = 0. 025). 
All such men experienced biochemical failure within 
66 months. In contrast, 60 % of the men who exhibited 
less than a two-fold increase, or decrease, in ANXA2 
abundance at the time of diagnosis were biochemical 
failure free after 66 months, and more than 35 % of them 
remained biochemical failure free at the trial end-point. 
The Kaplan–Meier curves for PSA using a three-fold 
cut-off for protein abundance in tumor relative to con-
trol tissue also demonstrated a significant difference in 
failure risk (log-rank Chi squared p = 0. 016) (Additional 
file 7). All men with greater than a three-fold increase in 
PSA abundance experienced biochemical failure within 
87  months, whereas more than 55  % of those with less 
than a three-fold increase remained biochemical failure 
free at the trial end-point.
Multivariate analysis, using Cox proportional haz-
ard modeling was applied to explore the relationship 
between the relative abundance change of each protein, 
modeled as continuous variables, and time to biochemi-
cal failure at the same time controlling for any difference 
in treatment employed (Table 1). Despite the small size of 
the dataset, and after controlling for all other protein rel-
ative abundance changes, the relative abundance change 
of ANXA2 in tumor versus control tissue was a signifi-
cant and independent predictor of the risk of biochemi-
cal failure (p = 0.018). The apparent association with PSA 
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Fig. 2 Strategy for selection of candidates for Western blot analysis. Potential candidates were initially selected from the set of 320 proteins 
identified by MS of radical prostatectomy sections by comparison with proteins annotated for PCa in the Human Protein Atlas (HPA, http://www.
proteinatlas.org) and then further selected by literature searches for known associations with PCa (Additional file 6). A refined set of four candidates 
was examined by Western blotting of archival FFPE specimens for prediction of risk of metastatic disease
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expression seen in the univariate analysis was not sup-
ported in the multivariate modeling.
ANXA2 is a 36  kDa peripheral membrane protein 
belonging to the 12 member annexin family of calcium 
binding proteins. ANXA2 is found on endothelial cells, 
early myeloid cells, and a variety of tumor cell types 
[17–20], and has been demonstrated to mediate cellular 
processes that are essential for cancer metastasis such 
as tumor cell migration [21, 22], invasion [23, 24] and 
adhesion [25]. Increased expression of ANXA2 has been 
reported in tumors of the breast, liver, and pancreas [23, 
26, 27]. There is debate surrounding the changes observed 
in ANXA2 abundance with different types of PCa. The 
expression of ANXA2 is reduced in high-grade prostatic 
intraepithelial neoplasia and in low- to moderate-grade 
PCa [28], but becomes elevated in high-grade PCa [10, 
29, 30]. Of interest also is the observation of Hood et al. 
[5] that ANXA2 apparently did not differ in abundance 
between cancer and benign hyperplasia regions of an 
FFPE block, although their analysis differs of course from 
our study of protein change that predicts disease out-
come. Shiozawa et al. demonstrated recently that ANXA2 
and its receptor are involved in PCa metastasis by regulat-
ing tumor cell migration and adhesion to osteoblasts and 
endothelial cells, as well as tumor cell proliferation at met-
astatic sites [30]. In contrast, Hailermarian et al. [31] did 
not find a statistically significant association of ANXA2 
or three other immunohistochemical markers with risk 
of PCa. Our demonstration that ANXA2 abundance in 
tumor versus control tissue at the time of diagnosis of 
localized, advanced PCa was significantly associated with 
disease progression therefore complements the immu-
nohistochemical analyses of sections from PCa and high 
grade prostatic intraepithelial neoplasia.
In summary, in this study we analyzed archival FFPE 
tissue from men with locally advanced PCa for whom 
there was ten-year outcome data for disease progression. 
In general, information about protein modification and 
Fig. 3 Representative Western blot images of matched tumor and 
control regions from patients with low or high risk of early bio-
chemical failure. Proteins were separated by 1D-PAGE, transferred 
to Hybond-LFP membrane and probed for ANXA2, AZGP1, PSA and 
PRDX1, plus actin as a loading control. Detection with AlexaFluor-
labelled second antibodies was captured using a FLA-5100 scanner
Fig. 4 Biochemical failure free survival as a function of Annexin A2 
risk stratification group. Kaplan–Meier estimator curves of time to bio-
chemical failure were constructed using an a priori selected two-fold 
increase in ANXA2 abundance in tumor relative to control tissue as 
the cut-point in each of the 16 cases. Statistical analysis of the failure 
demonstrated a significant difference in time to biochemical failure 
between the two groups (log-rank Chi squared p = 0. 025), indicating 
that a >2-fold change in ANXA2 abundance is predictive for early 
biochemical failure. Vertical lines on the Annexin A2 <2 curve denote 
censored cases
Table 1 Cox proportional hazard modeling of  target pro-
tein abundance and time to biochemical failure
a Dependent variable: time to biochemical failure (months)
b Biochemical failure did not occur within the trial period
c Radiotherapy plus either 3 or 6 months androgen deprivation therapy 
(Additional file 8)
Number Percent
Cases available in analysis Eventa 11 68.8
Censoredb 5 31.2
Total 16 100.0







ANXA2 0.427 0.181 0.018
AZGP1 −0.038 0.035 0.276
PRDX1 −0.165 0.108 0.127
PSA 0.135 0.101 0.181
Treatment armc 0.607 0.918 0.509
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abundance obtained by Western blotting complements 
histological description of the cellular localization of 
proteins. Our strategy was to use proteomic techniques 
to compile a database of abundant proteins for selec-
tion of candidates for subsequent multiplex Western blot 
analysis. Pauly et  al. [32] recently reported multiplexed 
antibody microarray analysis of proteins extracted from 
FFPE tissue. To our knowledge we describe the first 
application of multiplexed Western blotting for analysis 
of FFPE extracts from prostate biopsies. Our results com-
plement those of Geisler et  al. who used 2DE of frozen 
prostate specimens to show differences among proteins 
that included ANXA4 and A5, although they did not 
identify ANXA2, between patients with or without bio-
chemical relapse [6].
Looking forward, use of ELISA or focused mass spec-
trometry [33, 34] for measurement of individual or pan-
els of proteins from biopsy tissue may be used both for 
validation of prospective biomarkers and subsequently 
as diagnostic assays to enhance management of pros-
tate cancer. There may be additional potential to develop 
urine or blood-based assays, although for proteins 
including ANXA2 that are also elevated in other cancers 
[35] measurements on prostate biopsies would be needed 
for specific diagnosis.
Conclusions
In conclusion, this pilot proteomics study suggests that 
tumor expression of ANXA2 in diagnostic samples of a 
PCa may be predictive for the metastatic potential of that 
cancer. This study also suggests that PSA may have pre-
dictive potential. A larger study is in progress to examine 
and extend these findings using FFPE specimens from the 
Trans-Tasman TROG 03.04 trial [36] that is subsequent 
to the 96.01 trial used in the current study.
Methods
Study design and sample processing
FFPE tissue blocks containing prostate biopsies from 
Wellington men who entered the TROG 96.01 clinical 
trial were used in the current study. Proteomic studies 
on the biopsies were approved by the Wellington Eth-
ics Committee. The biopsies were collected from 1996 
to 2000 at the time of initial diagnosis before treatment 
and were immediately processed to FFPE blocks. The 
study design for TROG 96.01 has been described [2]. 
Eight hundred and eighteen men (ages 41–87), from Aus-
tralia and New Zealand, who had locally advanced PCa 
without distant metastases, received either radiotherapy 
alone or radiotherapy plus androgen deprivation for 3 or 
6 months. Benefits of androgen deprivation included bet-
ter control of serum PSA (biochemical control) and PCa 
specific survival. For the current proteomic study, tissue 
was included from 16 men who were treated with radia-
tion plus androgen deprivation [2]. For each man, the 
presenting tumor characteristics are provided in Addi-
tional file 8. The clinical endpoints were whether or not 
biochemical failure occurred, and if it did, the time from 
randomization to the event.
Initially, sections (20 µm thick, approximately 25 mm2) 
cut from a FFPE radical prostatectomy tissue block 
were used for investigation and optimization of protein 
extraction, 1DE, 2DE, MS and Western blotting. Pro-
tein recovery after incubation of 20  µm thick sections 
(approximately 25 mm2) in Extraction Buffer (see below) 
was 142 ±  58  µg protein/mg dry tissue (n =  2). Subse-
quently, Western blot analysis was carried out on pro-
teins extracted from tumor and control regions of FFPE 
needle biopsies for statistical analysis of protein asso-
ciation with disease outcome. Tissue harvesting for pro-
teomics was carried out by pathologists (BD and PF). 
FFPE sections (5 µm) from each block were stained with 
hematoxylin/eosin and examined to localize the site of 
the tumor. Tumor and control regions were excised from 
adjacent unstained sections under a dissecting micro-
scope. FFPE sections (10  µm) were deparaffinised at 
room temperature using 1  mL xylene (3× 2  min), fol-
lowed by rehydration in ethanol series (100 %, 90 %, 80 %, 
70 %, 5 min each) and air dried.
Deparaffinised, air-dried tissue samples were incubated 
in 250 µL of Extraction Buffer consisting of 40 mM Tris–
HCl (pH 8.2), 2 % SDS, and 3 % DTT (dithiothreitol) for 
1  h at room temperature followed by 20  min at 100  °C 
[37]. Samples were immediately centrifuged at 14,000×g 
for 15 min and each supernatant was added to 1.25 mL of 
Precipitation Solution (ProteoExtract® Protein Precipita-
tion Kit, EMD Millipore, Billerica, MA) and incubated 
overnight at −20 °C before centrifugation at 14,000×g for 
30 min at 4 °C. The protein pellets were washed 2× 5 min 
using 500 µL ProteoExtract® Wash Solution, air-dried 
for 5  min and resuspended in either rehydration buffer 
(7 M urea, 2 M thiourea, 2 % CHAPS, 20 mM DTT, 0.5 % 
immobilized pH gradient buffer, trace bromophenol 
blue) for 2DE; 1× LDS sample buffer containing Sample 
Reducing Agent (Invitrogen, Carlsbad, CA) for Gel-MS/
MS; or 50 mM Tris–HCl (pH 8.5), 8 M urea, 0.1 % SDS 
for LC–MS/MS. The protein concentration of each sam-
ple was assayed using a 2-D Quant Kit (GE Healthcare, 
Uppsala, Sweden). 1DE, 2DE, sample processing for mass 
spectrometry including digestion with sequencing-grade 
modified trypsin (Roche Applied Science, Penzberg, 
Germany), identification of proteins from 2DE gels by 
MALDI mass fingerprinting, and immunoblotting were 
carried out as previously described [38].
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Gel‑MS/MS
Protein extracts (30  µg) from FFPE tissue blocks were 
separated in triplicate by 1DE on 8  ×  8  cm 4–12  % 
NuPAGE gels and fixed for 90 min at room temperature 
in 50 % ethanol:3 % orthophosphoric acid, then washed 
3× with water. Each sample lane was sliced horizon-
tally into 30–35 slices that were then transferred to the 
wells of a 96-well microtiter plate and processed in a GE 
Healthcare Ettan digester. Each gel piece was diced into 
approximately 1 mm3 cubes, destained using 50 % meth-
anol:50  mM NH4HCO3 (3× 45  min), and air-dried for 
2  h. Proteins were digested for 6  h using 10  µL trypsin 
solution (2.5  ng/µL trypsin in 20  mM NH4HCO3) per 
well. Digest peptides were extracted using ACN (acetoni-
trile):0.1  % TFA (trifluoroacetic acid) 1:1 (3× 45  min), 
air-dried, then resuspended in 2 µL 10 mg mL−1 CHCA 
(alpha-cyano-4-hydroxycinnamic acid) in ACN:0.1  % 
TFA 1:1 and spotted onto an ABSCIEX 5800 MALDI 
TOF/TOF target plate.
LC–MS/MS
Total protein extracts (50  µg) were reconstituted over-
night at 4 °C in 50 µL of 50 mM Tris–HCl (pH 8. 5), 8 M 
urea, 0.1  % SDS. Proteins were reduced in 5  mM DTT 
for 1  h, alkylated for 30  min in 10  mM iodoacetamide, 
and quenched in 15 mM DTT, all at room temperature. 
Samples were diluted 10-fold by the addition of 450 µL 
of 50  mM Tris–HCl (pH 8.5) and digested overnight 
at room temperature using 2.5  µg of trypsin per sam-
ple. Digests were lyophilised, resuspended in 500 µL 
0.1  % TFA and purified using Omix C18 reverse-phase 
100 µL tips (Agilent Technologies, Santa Clara, CA). 
Peptides were eluted into 100 µL of ACN:0.1  % TFA 
7:3, lyophilised, and resuspended in 30 µL 0.1  % TFA. 
Reverse-phase LC-MALDI was performed in triplicate 
using a TEMPO LC-MALDI spotter system (AB SCIEX, 
Framingham, MA) with a 150  ×  0.1  mm Chromolith® 
CapRod® RP-18e monolithic column (Merck Milli-
pore, Billerica, MA). Five microlitres of each sample was 
injected into a 3 µL sample loop at 1 µL min−1. Peptide 
separation was achieved using a mobile phase system 
comprised of 2 % ACN, 0.1 % TFA (Reagent A) and 98 % 
ACN-0.1 %TFA (Reagent B) with a 36 min linear gradient 
of 0–80 % Reagent B at 1 µL min−1. Eluted peptides were 
mixed on-line with MALDI matrix (CHCA in ACN-0.1 % 
TFA 1:1 at 1 µL min−1) and spotted at 16 s intervals onto 
an ABSCIEX 5800 target plate.
Mass spectrometry and database searches
Gel-MS/MS and LC–MS/MS spectra were collected 
using an ABSCIEX 5800 MALDI TOF/TOF mass spec-
trometer in positive ion mode. TOF/TOF data files were 
searched against UniProtKB human sequences (88,473 
sequences, final searches 17 January 2014) using Protein-
Pilot v3.0 (AB SCIEX) with the Paragon algorithm [39]. 
Search parameters were maximum one missed trypsin 
cleavage, maximum 50 ppm and 0.2 Da mass tolerances 
for MS and MS/MS spectra respectively, cysteine carba-
midomethylation as a fixed modification, and methionine 
oxidation as a variable modification. Paragon searches 
were conducted in “Thorough Mode” using a reversed 
sequence database to obtain 95  % peptide identification 
confidence. The mass spectrometry proteomics data have 
been deposited to the ProteomeXchange Consortium 
(http://www.proteomexchange.org) via the PRIDE part-
ner repository [40] with the dataset identifier PXD000963 
and doi 10.6019/PXD000963.
Western blotting
Western blot analysis was carried out on proteins 
extracted from tumor and control regions of FFPE nee-
dle biopsies for statistical analysis of protein associa-
tion with disease outcome. Protein extracts (15–20  µg 
protein) were resolved by 4–12  % 1D-PAGE and trans-
ferred to Hybond-LFP membranes (GE Healthcare) for 
1 h at 30 V. The membranes were blocked in PBS con-
taining 0.1 % Tween-20 and 0.25 % gelatin for 90 min at 
room temperature and then probed overnight at room 
temperature with the following antibodies: ANXA2 
(C-10, mouse monoclonal, Santa Cruz, sc-28385) 1:100; 
PSA (C-19, goat polyclonal, Santa Cruz, sc-7638) 1:200; 
PRDX1 (N-19, goat polyclonal, Santa Cruz, sc-7381) 
1:200; AZGP1 (H123, rabbit polyclonal, Santa Cruz, 
sc-11358) 1:200. Membranes were then incubated 
sequentially for 1 h at room temperature with the follow-
ing fluorophore conjugated secondary antibodies: Alex-
aFluor®647 goat anti-rabbit IgG (H+L), AlexaFluor®555 
goat anti-mouse IgG (H+L), and AlexaFluor®647 
chicken anti-goat IgG (H+L), all 1:2500. Images were 
acquired immediately after incubation with each sec-
ondary antibody using a FLA-5100 fluorescent scanner 
(FujiFilm, Tokyo, Japan), and signal intensity was quan-
tified using ImageJ™ software [41]. Each membrane 
was also probed for 3 h at room temperature with anti-
actin primary antibody (mouse monoclonal, Chemicon, 
MAB1501) followed by AlexaFluor®555 goat anti-mouse 
IgG (H+L) 1:2500. The intensity of each band was meas-
ured in triplicate to establish a mean signal intensity and 
standard deviation for each protein including the actin 
loading control. The mean values for each protein were 
normalized to the relevant actin control values and rela-
tive abundance changes for each protein were calculated 
as the ratio of normalized tumor to control tissue signal 
intensity. Protein abundance analysis was performed 
without knowledge of disease outcome for each of the 
clinical samples.
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Statistical methods
SPSS software was used for statistical analysis (IBM SPSS 
Statistics 22.0—August 2013). The association of protein 
abundance measurements with time to biochemical fail-
ure was assessed in a univariate way using the Kaplan–
Meier estimator for the survival function with cut-points 
chosen a priori while multivariate associations with bio-
chemical failure were assessed by application of Cox pro-
portional hazard modeling.
Western blot signals were undetectable in 9.4  % of the 
160 individual protein relative abundance measurements 
(four target proteins plus actin measured in tumor and 
control tissue for each the 16 cases). Missing values were 
imputed with a value that was approximately 50 % of the 
lowest detectable value for any protein in either tissue type.
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